Panelists discuss recent phase 3 trial results of a novel oral agent for idiopathic pulmonary fibrosis (IPF) and progressive ...

Panelists discuss exciting phase 3 trial data on a novel selective phosphodiesterase inhibitor that elevates intracellular ...

Long-term CARTITUDE-1 data show ciltacabtagene autoleucel (cilta-cel) may offer lasting remission and survival in relapsed/refractory multiple myeloma, according to Sundar Jagannath, MBBS, of the ...

Panelists discuss how incorporating subcutaneous (SubQ) formulations into clinical formularies requires careful evaluation of clinical equivalence, workflow fit, and reimbursement logistics, with ...

Richard Lafayette, MD, FACP, explains why a REMS program is not required for the endothelin A receptor antagonist and how ...

Explore how the Specialty Medical Home model transforms care for patients with inflammatory bowel disease (IBD) by ...

An analysis of 1.7 million patients shows semaglutide may significantly reduce Alzheimer and vascular dementia risk compared ...

A model that can estimate the need for pre-exposure prophylaxis (PrEP) in the US can help to clarify use patterns to address ...

Americans with obesity face almost double the financial hardship as their peers without obesity, according to a study published in Annals of Internal Medicine that highlighted not ...

In a cohort of TRANSCEND FL, the chimeric antigen receptor T-cell therapy liso-cel showed a 95% overall response rate in relapsed marginal zone lymphoma, offering hope for improved patient outcomes in ...

Model predicts millions of cases, hospitalizations, and deaths if routine childhood vaccination rates decline significantly.

In this interview, Richard J. Nowak, MD, MS, principal investigator of the MINT trial of inebilizumab for generalized myasthenia gravis (gMG), discusses the trial’s key findings, including significant ...